Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • News
    • pharma-news
    • Ibuprofen and...

    Ibuprofen and Covid-19: Drugmaker Sanofi defends Molecule, WHO updates its stand

    Medical Dialogues BureauWritten by Medical Dialogues Bureau Published On 2020-03-21T13:35:23+05:30  |  Updated On 21 March 2020 1:35 PM IST
    Ibuprofen and Covid-19: Drugmaker Sanofi defends Molecule, WHO updates its stand

    New Delhi: Responding to the World Health Organisation statement earlier that recommended avoidance of Ibuprofen due to its suspected worserning of COVID-19 reported by some french officials , French Pharma major Sanofi on Friday said there is currently no scientific evidence establishing a link between ibuprofen and worsening of COVID-19.

    Sanofi is one of the largest makers of Ibuprofen, with its popular brand Combiflam ( paracetomol and ibuprofen combination) being widely used in India.

    Medical Dialogues had earlier reported about the World Health Organisation recommended that people suffering from Covid-19 symptoms avoid taking ibuprofen after French officials warned that anti-inflammatory drugs could worsen the effects of the virus. The minister, Oliver Veran, tweeted on Saturday 14 March that people with suspected COVID-19 should avoid anti-inflammatory drugs. "Taking anti-inflammatory drugs (ibuprofen, cortisone . . .) could be an aggravating factor for the infection. If you have a fever, take paracetamol," he stated.

    Read Also: No Ibuprofen For COVID-19 Patients Says WHO

    Countering it, Sanofi said the WHO has stated they are not aware of published clinical or population-based data on ibuprofen and the worsening of COVID-19 and based on currently available information, do not recommend against the use of ibuprofen.

    "At Sanofi, our priority is the safety of our consumers, patients, employees, their families and the communities we are engaged with and ensuring the continuous supply of safe and efficacious products," Sanofi said in a statement.

    As very recently stated by several health authorities, including European Medicines Agency (EMA), there is currently no scientific evidence establishing a link between ibuprofen and worsening of COVID-19, it added.

    In line with EU national treatment guidelines, healthcare professionals can continue prescribing (non-steroidal anti-inflammatory drugs) NSAIDs (like ibuprofen) for patient use, as per locally approved product information, it said.

    The company is monitoring the situation closely and will review any new information that becomes available on this issue in the context of the pandemic, it added.

    Read also: Regeneron, Sanofi begin testing use of Arthritis Drug Kevzara to treat COVID-19

    Meanwhile, WHO through a tweet also issued its updated stand on the matter yesterday

    Q: Could #ibuprofen worsen disease for people with #COVID19?

    A: Based on currently available information, WHO does not recommend against the use of of ibuprofen. pic.twitter.com/n39DFt2amF

    — World Health Organization (WHO) (@WHO) March 18, 2020


    sanoficovid-19coronavirusibuprofencoronavirus test

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Medical Dialogues Bureau
    Medical Dialogues Bureau

      Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers.  Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in. Check out more about our bureau/team here

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok